Lincoln Krochmal, MD, FAAD

President & Chief Executive Officer

Dr. Lincoln Krochmal is a board certified Dermatologist with over 25 years experience in the pharmaceutical and consumer goods industries. Prior to joining Excaliard as president and CEO and a member of the BOD in September 2008, Dr. Krochmal served as Executive Vice President, Research and Product Development for Connetics Corporation, a specialty dermatology company headquartered in Palo Alto, CA, until the company’s acquisition by Stiefel Laboratories, Inc. Dr. Krochmal began his industrial career with Westwood Pharmaceuticals (the dermatology subsidiary of Bristol-Myers Squibb) becoming VP, Dermatology Research & Development and VP, Worldwide Medical Development. He then joined Unilever PLC, where he spent the next decade in various executive management positions including SVP, Home and Personal Care Research & Development directing the worldwide development of numerous consumer products including helping to build the Dove® brand to a $ 2 billion dollar global business.

During his career, Dr. Krochmal has played a pivotal role in the approval of 15 NDAs/ANDAs for new topical dermatologicals including LacHydrin®, Ultravate®, Dovonex®, Evoclin®, Verdeso®, Olux-E® and Extina® and numerous OTC and consumer goods in the US and internationally.

Dr. Krochmal received his Doctor of Medicine from the Medical College of Wisconsin, and is board certified in dermatology. Dr. Krochmal serves on the board of directors for the International Academy of Cosmetic Dermatology and Quinnova Pharmaceuticals, Inc. He is a fellow of the American Academy of Dermatology, a Diplomat of the American Board of Dermatology, a member of the International Society of Dermatology and the Dermatology Foundation.

Nicholas M. Dean, Ph.D.

Founder and Chief Scientific Officer

Prior to founding Excaliard in the spring of 2006, Dr. Dean served for four years as Vice President of Functional Genomics and Oncology at Isis Pharmaceuticals where he also served as Managing Director, Isis Singapore. Dr. Dean originally joined Isis Pharmaceuticals in 1991 and served in various roles in the molecular pharmacology department until 2000 at which time he became Executive Director and Vice President, Functional Genomics for Isis Pharmaceuticals. Dr. Dean received his Ph.D. in Pharmacology from the Welsh National School of Medicine. He then spent time conducting research at the National Cancer Institute and the University of Hawaii before joining Isis Pharmaceuticals. Dr Dean has authored more than 110 scientific papers, and more than 50 issued patents.

Jeff Jensen

Head of Clinical Operations

Jeff Jensen brings to Excaliard over 25 years of clinical operations experience and has successfully overseen the outsourcing of hundreds of clinical trials. Prior to joining Excaliard, he was Senior Director of Clinical Operations at Metabasis Therapeutics and a Director of Study Management and Development Operations at Pfizer. In addition, Mr. Jensen has held senior level positions at some of the industry's top clinical research organizations. He was Vice-President of Operations at INC Research, a leading CNS and oncology CRO, Chief Operating Officer for Therapeutic Management, and Director of Clinical Operations at Quintiles. Before joining INC Research he gained international experience as Director of Clinical Research in Europe at Pharmaco LSR (currently PPD). Mr. Jensen earned a Bachelor of Science degree in Biochemistry and Biophysics at Oregon State University.

Ian Wisenberg, CPA

Chief Financial Officer

Ian Wisenberg has more than 25 years experience in international business with an emphasis in finance, capital formation, business development and administration.

He is founder and managing partner of BioGlobal Consulting Group (BGCG).

Prior to founding BioGlobal Consulting Group, he served as the Senior Vice President of Business Development and CFO of BIOCOM – the world’s largest regional life science trade organization.

Bringing a broad portfolio of expertise, Ian has a solid track record in Capital Development initiatives aimed at establishing strategic financial partnerships with local, national and international financing institutions. He was also responsible for the VC incubator in San Diego. Of equal significance is his ability to foster international relations with government agencies and private institutions.

Mr. Wisenberg also serves on the Board of Directors for two local biotech companies and is treasurer for the San Diego Venture Group.

Prior to BIOCOM, he was Vice President of finance and administration, as well as interim President, Secretary and treasurer of Aerocast, Inc., a secured broadband media streaming company.

Mr. Wisenberg holds a Bachelor of Commerce Degree in accounting from Cape Town University and is a Certified Public Accountant.

Gary Gentzkow, M.D.

Chief Medical Officer

Dr. Gentzkow is an Internal Medicine physician with a 30+ year career entirely devoted to developing new medical therapies—pharmaceutical, biological & cellular, and medical devices. For the past 20 years, Dr. Gentzkow has focused on wound healing and other skin-related research, particularly using celluar therapies, including engineered human tissues, a field in which he has lectured and published extensively.

Earlier in his career, at Abbott Laboratories, American Critical Care, 3M Pharmaceuticals and Synergen, he directed the clinical development programs for several classes of pharmaceuticals: antiarrhythmics, cardiovascular, critical care, pulmonary, antiinfective, antiinflammatory, muscle relaxant/analgesic products, growth factors and electrical stimulation for wound healing. From 1992-2006 at Advanced Tissue Sciences and Smith & Nephew, Dr. Gentzkow headed the clinical research programs for the engineered human tissues, Dermagraft® and TransCyte®, FDA-approved for diabetic foot ulcers and burns respectively. He has also directed clinical aspects of research programs on cartilage, blood vessels, and cardiovascular regeneration. He has published numerous articles and presented extensively around the world in the field of wound healing and cardiovascular medicine.

During his career he has had primary responsibility for the clinical development and market introduction of several drugs and biologics that have achieved FDA approval including Bretylol (bretylium tosylate),Tamobocr (flecainide acetate), IV dopamine, IV nitroglycerin, Dermagraft®, TransCyte®, Nouricel™, and human collagen.

Dr. Gentzkow received his A.B. degree cum laude from Harvard University and earned his M.D. degree from the University of Oregon Health Sciences Center.

Elizabeth Gordon, Ph.D.

Head of Regulatory Affairs and Project Management

Dr. Elizabeth Gordon is a recognized expert in regulatory affairs with 18 years experience in the pharmaceutical industry and at the FDA. Dr. Gordon has an in-depth understanding of the requirements for successful new drug registration along with a first-hand appreciation for facilitating interactions with the FDA.

In addition to her position as Head of Regulatory Affairs and Project Management at Excaliard Pharmaceuticals, Dr. Gordon is President of EG Consulting, Inc., where she provides expert regulatory advice on requirements for biological and pharmaceutical product development.

Dr. Gordon also served as Senior Director, Regulatory Affairs, in the Medical and Regulatory Services Division of Quintiles Transnational, where she assisted clients in the development of efficient worldwide product development programs and provided strategic regulatory advice on all aspects of therapeutic development from discovery through post-marketing. She also assisted clients with communications with regulatory agencies and the preparation of all regulatory filings.

Prior to Quintiles, Dr. Gordon spent 6 years at the Food and Drug Administration serving as Special Assistant to the Director, Office of Vaccines Research and Review, and Acting Associate Director for Regulatory Policy, Office of Therapeutics Research and Review in the Center for Biologics Evaluation and Research (CBER). She also served as a reviewer of INDs and BLAs for numerous biological products, and was a reviewing microbiologist in the Division of Anti-Infective Drug Products in the Center for Drug Evaluation and Research. At CBER, she was instrumental in developing policy for the regulation of biological products. Dr. Gordon also coordinated numerous sessions of advisory committee meetings for CBER.

Dr. Gordon has a Ph.D. in Microbiology from the University of Rhode Island and received a B.A. in Microbiology from the University of New Hampshire. She also completed an Executive M.S. in Technology Management at the University of Maryland.